Lei Chen

Lei Chen

Auto-generated profile, based on publicly available information

Lei Chen

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genetics, Peking University Cancer Hospital and Institute, Beijing, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
LCLei Chen
Lei Chen
HWHui Wang
Hui Wang
ZQZifan Qi
Zifan Qi
LLLinlin Liang
Linlin Liang
CGChuanhai Guo
Chuanhai Guo
YKYang Ke
Yang Ke
PURPOSE: To characterize the pattern of post-treatment quality of life (QoL) for esophageal cancer (EC) survivors and construct models predicting their long-term QoL. METHODS: On the basis of a randomized trial in an EC high-risk region in China, we interviewed 363 EC survivors and 25,245 permanent residents matched with the survivors on age, sex, and township as the baseline. QoL was measured using three-level version of European Quality of Life 5-Dimensions instrument. We constructed piecewise mixed models estimating the QoL of EC survivors that varied by age, sex, patient type, hospital level, and therapy to ascertain QoL determinants. RESULTS: The post-treatment QoL of EC survivors dropped by 15.7% within the first year and recovered by 9.3% between 1 and 9 years compared with the baseline. Therapy was found to be a determinant of QoL, and a series of therapy-specific models were fitted accordingly, which all showed the pattern of decreasing rapidly and recovering gradually. Endoscopic treatment had the least impact on post-treatment QoL (7.5% drop within 5 years) compared with esophagectomy (12.2% drop within 1 year) and chemoradiotherapy (37.8% drop within 2 years). The usual activities dimension showed the greatest impairment among those patients (34.4% drop within 1 year). CONCLUSION: This community-based study described the long-term QoL trajectory for EC survivors after different therapeutic modalities and constructed models to predict therapy-specific QoL at different time points after treatment. It provided new insights into decision making in treatment for EC from the perspective of QoL protection, offering a convenient tool for estimating quality-adjusted life-years.

5 August 2025 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
HTHongrui Tian
Hongrui Tian
MLMengfei Liu
Mengfei Liu
ZLZhen Liu
Zhen Liu
CSChao Shi
Chao Shi
LCLei Chen
Lei Chen
YKYang Ke
Yang Ke

1 July 2026 in JCO Global Oncology
Verified
Journal Article
Open access
ZYZeyu Yan
Zeyu Yan
LCLei Chen
Lei Chen
JMJinbao Ma
Jinbao Ma
MLMengfei Liu
Mengfei Liu
ZLZhen Liu
Zhen Liu
YKYang Ke
Yang Ke
PURPOSE: The purpose of this study was to identify participation determinants among high-risk individuals in risk-stratified upper GI (UGI) cancer screening. METHODS: This sequential mixed-methods study was conducted in a population-based UGI cancer screening program in Ningxia Province, China. It integrates quantitative and qualitative methods to comprehensively examine participation determinants. Between April and December 2023, quantitative data were collected from 2,571 high-risk individuals identified by validated diagnostic models. Subsequently, 42 high-risk individuals (median age: 63.0 years; 81.0% male) were interviewed by stratified purposive sampling from March to April 2024. Logistic regression explored factors associated with screening adherence. Thematic analysis of qualitative interviews integrated quantitative findings using the Capability, Opportunity, and Motivation-Behavior framework. RESULTS: Of the high-risk individuals, 52.8% declined endoscopy. Nonparticipation was significantly associated with older age (adjusted odds ratio [aOR], 1.28 [1.06-1.54]), male sex (1.31 [1.01-1.70]), Hui ethnicity (1.35 [1.12-1.62]), nonsmoking (1.23 [1.01-1.50]), nondrinking (1.36 [1.09-1.71]), no family history of UGI cancer (1.48 [1.20-1.84]), fewer UGI symptoms (2.64 [2.19-3.18]), and no prior UGI examination (1.67 [1.37-2.05]). In the qualitative phase, seven key barriers were identified, including insufficient knowledge about UGI cancer and risk assessment, physical limitations, low perceived risk, gastroscopy-related fears, cost concerns, time constraints, and inadequate information. CONCLUSION: Addressing limited knowledge and program accessibility may improve participation and real-world implementation of risk-stratified UGI cancer screening.